摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3-ethyl-5-(2-(1-methoxypropan-2-yloxy)-5-(4-propylpiperazin-1-ylsulfonyl)pyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one | 247581-96-0

中文名称
——
中文别名
——
英文名称
(R)-3-ethyl-5-(2-(1-methoxypropan-2-yloxy)-5-(4-propylpiperazin-1-ylsulfonyl)pyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one
英文别名
3-ethyl-5-[2-[(2R)-1-methoxypropan-2-yl]oxy-5-(4-propylpiperazin-1-yl)sulfonylpyridin-3-yl]-2-methyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
(R)-3-ethyl-5-(2-(1-methoxypropan-2-yloxy)-5-(4-propylpiperazin-1-ylsulfonyl)pyridin-3-yl)-2-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one化学式
CAS
247581-96-0
化学式
C24H35N7O5S
mdl
——
分子量
533.652
InChiKey
OXYHJDREXPHWMX-MRXNPFEDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    37
  • 可旋转键数:
    10
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    140
  • 氢给体数:
    1
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Highly potent and selective chiral inhibitors of PDE5: An illustration of Pfeiffer’s rule
    作者:Mark E. Bunnage、John P. Mathias、Anthony Wood、Duncan Miller、Stephen D.A. Street
    DOI:10.1016/j.bmcl.2008.10.037
    日期:2008.12
    A series of potent chiral PDE5 inhibitors are described that are based on the sildenafil architecture but exhibit much greater selectivity over PDE6. Eudismic analysis of the SAR in this series provided a clear illustration of Pfeiffer's rule and indicated that the chiral motif was involved in a highly-stereoselective interaction with PDE5. This PDE5 specificity translated to levels of selectivity over PDE6 that were hitherto unprecedented in the sildenafil scaffold. UK-371,800 (compound 8) was identified as a development candidate from this series that married sildenafil-like molecular properties with high selectivity over PDE6. Clinical data confirm that UK-371,800 has markedly superior human pharmacokinetics to a previously-described higher molecular weight achiral analogue in this template (compound 1). (C) 2008 Elsevier Ltd. All rights reserved.
查看更多